Shanghai Pharmaceuticals (China) Investor Sentiment

601607 Stock   19.42  0.43  2.26%   
About 55% of Shanghai Pharmaceuticals' investors are presently thinking to get in. The analysis of overall sentiment of trading Shanghai Pharmaceuticals Holding stock suggests that some investors are interested at this time. The current market sentiment, together with Shanghai Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Shanghai Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
  
23 hours ago at news.google.com         
Shanghai Pharmaceuticals Declares Final Dividend for 2024 - TipRanks
Google News at Macroaxis
few days ago at news.google.com         
Shanghai Pharmaceuticals Subsidiary Penalized for Anti-Monopoly Violations - TipRanks
Google News at Macroaxis
over a week ago at news.google.com         
Shanghai Pharmaceuticals Announces Board Meeting for Annual Results and Dividend Consideration - Tip...
Google News at Macroaxis
over three weeks ago at news.google.com         
Shanghai Pharmaceuticals Expands Stake in SHPL with Strategic Acquisition - TipRanks
Google News at Macroaxis
over two months ago at news.google.com         
Shanghai Pharmaceuticals Nominates Dr. WAN Jun to Enhance Board Diversity - TipRanks
Google News at Macroaxis
over two months ago at news.google.com         
Chinese Cancer Drug Developer Hutchmed Sharpens RD Focus, Divests Non-Core JV For Over 600 Million -...
Google News at Macroaxis
over two months ago at news.google.com         
Shanghai Pharmaceuticals Expands Stake in SHPL - MSN
Google News at Macroaxis
over six months ago at news.google.com         
Shanghai Pharmaceuticals Declares Interim Dividend - TipRanks
Google News at Macroaxis
over six months ago at news.google.com         
Shanghai Pharmaceuticals Holding Second Quarter 2024 Earnings Revenues Disappoint - Simply Wall St
Google News at Macroaxis
over six months ago at news.google.com         
Shanghai Pharma Reports Profit, Plans Dividend - TipRanks
Google News at Macroaxis
over six months ago at news.google.com         
Shanghai Pharmaceuticals Holding Co., Ltd Short Interest Update - American Banking and Market News
Google News at Macroaxis
over six months ago at news.google.com         
Investing in Shanghai Pharmaceuticals Holding five years ago would have delivered you a 22 percent g...
Google News at Macroaxis
over six months ago at news.google.com         
Shanghai Pharmaceuticals Announces AGM Outcomes - TipRanks
Google News at Macroaxis
over six months ago at news.google.com         
Shanghai biotech firms shares soar after Fosuns US690 million buyout offer - South China Morning Pos...
Google News at Macroaxis
over six months ago at news.google.com         
Shanghai Pharmaceuticals Holding Co., Ltds market cap surged CN2.3b last week, private companies who...
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Shanghai Pharmaceuticals that are available to investors today. That information is available publicly through Shanghai media outlets and privately through word of mouth or via Shanghai internal channels. However, regardless of the origin, that massive amount of Shanghai data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Shanghai Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Shanghai Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Shanghai Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Shanghai Pharmaceuticals alpha.

Shanghai Pharmaceuticals Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Shanghai Pharmaceuticals Nominates Dr. WAN Jun to Enhance Board Diversity - TipRanks
01/10/2025
2
Shanghai Pharmaceuticals Subsidiary Penalized for Anti-Monopoly Violations - TipRanks
03/21/2025

Complementary Tools for Shanghai Stock analysis

When running Shanghai Pharmaceuticals' price analysis, check to measure Shanghai Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Shanghai Pharmaceuticals is operating at the current time. Most of Shanghai Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Shanghai Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Shanghai Pharmaceuticals' price. Additionally, you may evaluate how the addition of Shanghai Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Share Portfolio
Track or share privately all of your investments from the convenience of any device
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences